



## LACTIC ACID AS SPACER BETWEEN POLY ACRYLIC ACID AND 4-AMINOANTIPYRINE

Fiyral Mohammad Ali<sup>1</sup> --- Taghreed Hashim.AL-Noor<sup>2†</sup> --- Saif Mohsin Ali<sup>3</sup>

<sup>1,3</sup> AL-Mustansiriya University, College of Science, Department of Chemistry, Baghdad, Iraq

<sup>2</sup> Ibn -Al-Haithem College of Education for pure science, Baghdad University, Iraq

### ABSTRACT

*Due to many problems associated with drug release and side effects, we could design a novel drug delivery system through modification of poly acrylic acid (AA) with Lactic acid as a spacer between the polymer and 4-aminoantipyrine. In vitro drug release had been conducted successfully in basic medium in pH 7.4 and acidic medium in pH 1.1 at 37°C. The prepared prodrug polymer was characterized by FTIR and <sup>1</sup>H-NMR spectra. Physical properties and intrinsic viscosity of drug polymer were determined. The good results were obtained in the presence of spacer unit with comparing without spacer unit.*

© 2015 Pak Publishing Group. All Rights Reserved.

**Keywords:** Poly acrylic acid, Lactic acid, Prodrug polymer.

### Contribution/ Originality

This study contributes in the existing literature Synthesized compound from lactic acid as spacer between poly acrylic acid and 4-aminoantipyrine. This study uses new estimation methodology several physical tools .This study originates new formula.

### 1. INTRODUCTION

4-aminoantipyrine is a biologically active compound and its analogues and other pyrazole derivatives have shown anti-inflammatory, analgesic, antiviral, and antipyretic properties (Alam *et al.*, 2012; Radi *et al.*, 2012). Dipyron and some (AA) derivatives have a high potential to attenuate or prevent the anti-platelet effects of aspirin (Yi *et al.*, 2013). Poly lactic acid is at present one of the most promising biodegradable polymers (biopolymers) and has been the subject of abundant literature over the last decade. PAA can be processed with a large number of techniques and is

† Corresponding author

DOI: 10.18488/journal.57/2015.4.6/57.6.36.45

ISSN(e): 2306-6148/ISSN(p): 2306-9864

© 2015 Pak Publishing Group. All Rights Reserved.

commercially available (large-scale production) in a wide range of grades. It is relatively cheap and has some remarkable properties, which make it suitable for different applications. and its biocompatibility in contact with living tissues is exploited for biomedical applications (implants, sutures, drug encapsulation (Avérous, 2011). The basic aim of prodrug design is to mask undesirable drug properties, such as low solubility in water or lipid membranes, low target selectivity, chemical instability, undesirable taste, irritation or pain after local administration, pre systemic metabolism and toxicity (Rautio *et al.*, 2008; Testa, 2009; Stella, 2010). In a polymer-drug conjugate, there are at least three major components: a soluble polymer backbone, a biodegradable linker, and a covalently linked anti-cancer drug which is deactivated as a conjugate, (Figure 1) (Duncan, 2006; Xinxin, 2010).




Figure-1. Major components of a polymer-drug conjugate (Xinxin, 2010)

This research concern to minimize delivery problems and reduced gastrointestinal side effects by controlling the rate of hydrolysis, and duration of drug action.

## 2. EXPERIMENTAL

### 2.1. Materials and Instruments

The following chemicals were used as received from suppliers; 4-Aminoantipyrine was purchased from Samarra Company; Thionyl chloride was obtained from Fluka. Lactic acid, Acrylic acid and solvents were obtained from Aldrich. Dimethylformamide was purchased from Merck. Triethylamine was purchased from Fluka. <sup>1</sup>H-NMR spectra were recorded on a Shimadzu spectrophotometer in Dimethylsulphoxide (DMSO). The FTIR spectra were recorded by (4000-400cm<sup>-1</sup>) on a Shimadzu spectrophotometer. Melting points were determined on Callenkamp MF B-600 Melting point apparatus. Electronic spectra measurement using CINTRA5-UV-Visible spectrophotometer.

### 3. POLYMERIZATION OF ACRYLIC ACID (Firyal, 1997)

In a screw capped polymerization bottle (3g.), of acrylic acid was dissolved in (10 ml) of DMF, (0.05%) of the monomer weight of di-benzoyl peroxide was added as an initiator. The bottle was flushed with nitrogen for few minutes inside a glove and firmly stopped. The solution was maintained at 90°C, using water bath for 1 hr. The solvent was evaporated under vacuum; the product was obtained, washed three times with ether. Dried in a vacuum oven at 50°C, produced 95% of polymer with  $\mu_{in} = 0.46$  dL/g.

### 4. PREPARATION OF POLYACRYLOYL CHLORIDE (Diab, 2003)

A thionyl chloride (5ml., 0.04mole) was added gradually to a mixture (2.48g, 0.04mole) of polyacrylic acid which was dissolved in 15ml of dioxane placed in a round-bottom flask provided with condenser, the contents were stirred with a magnetic bar at room temperature. The excess of thionyl chloride was distilled off and the polyacryloyl chloride was isolated and dried. Producing white polymer, it was collected on a glass filter, washed repeatedly with ether giving 90%.

### 5. MODIFICATION OF POLYACRYLOYL CHLORIDE WITH LACTIC ACID(P<sub>2</sub>) (Peter and Renata, 2002)

In a round bottom flask provided with condenser (3g., 0.041mole) of polyacryloyl chloride was dissolved in 10ml of DMF. Then (3.75g., 0.041mole) of Lactic acid the mixture was refluxed with stirring for 2hrs, the viscous product was obtained, the solvent was evaporated, washed with ether and dried at room temperature. The polymer (P<sub>2</sub>) was obtained with 69% as a yellowish brown viscous polymer.

### 6. SUBSTITUTION OF POLY [2-((2-METHYLBUTANOYL) OXY) PROPIONIC] WITH 4-AMINOANTIPYRINE(P<sub>3</sub>) (Callery and Peter, 2002)

(1g., 0.007mole) of prepared polymer (P<sub>2</sub>), was dissolved in dioxane: DMF mixture (10:1vol.), and (1ml) thionyl chloride was added, the mixture was heated at 50°C the prepared acyl chloride and (1ml) of triethylamine was added to dissolved (1.41g., 0.007mole) 4-aminoantipyrin, the mixture was refluxed with stirring for 2hrs. The solvent was evaporated under vacuum; the product was washed

with water three times, dried under vacuum oven. The reddish brown polymer ( $P_3$ ) was obtained with 65%. The yield % of produced polymer was as a viscous material.

## 7. DETERMINATION OF DEGREE OF LACTIC ACID SUBSTITUTION (Soudabeh and Ali, 1996)


(5mg) of prepared pro-drug polymer ( $P_3$ ) was dissolved in (2ml) of 0.1 N NaOH, the solution was heated to 70°C, for 15min in a water bath, cooled and the resulting solution was titrated with 0.1N HCL to determine the excess of Na OH solution.

## 8. CONTROLLED DRUG RELEASE (Drug, 2003; Firyal, 2005; Johnson *et al.*, 2005; Ardeshir *et al.*, 2007; Debjit *et al.*, 2012)

(0.1g.) of dried prepared pro-drug polymer ( $P_3$ ) was poured in (100ml) of aqueous buffer solution such as (phosphate buffer pH 7.4) or acidic (solution pH 1.1). The buffer solution maintained at 37°C., with continuously stirred and (3ml) of sample was analyzed by UV spectrophotometer and compared with calibration curve which was obtained computerized under similar medium. Fig.(5), showed controlled 4-Aminoantipyrene release in different pH values at 37°C.

## 9. RESULTS AND DISCUSSION

In this research, the pro-drug was prepared using di-functional spacer groups such as Lactic acid which was inserted between the Lactic acid and poly acryloyl chloride. The carboxylic acid groups was reacted with OH groups of Lactic acid, produced ester as attachment group, and the other carboxyl groups were reacted with 4-aminoantipyrene produced amide arm groups. This work aimed to extend the drug pended units to be easy hydrolysis through polymer chains. The high yield was obtained. The reaction was explained as Scheme 1.:



Scheme 1

The modified polymer P<sub>2</sub> and P<sub>3</sub> were characterized, by FTIR spectrum, Fig (1) shows the broad beak around 3441 cm<sup>-1</sup> assigned to the remained -OH carboxylic acid of poly acrylic acid, 3392cm<sup>-1</sup> due to the hydroxyl group of substituted lactic acid group,

2974 cm<sup>-1</sup> of C-H aliphatic. 2785cm<sup>-1</sup> of CH<sub>3</sub> methyl, 1718 cm<sup>-1</sup> represented to (ester carbonyl) and 1730 cm<sup>-1</sup> due to carbonyl of carboxylic group of unreacted poly acrylic acid and 1126 cm<sup>-1</sup> of C-O ester. Fig (2), <sup>1</sup>H-NMR spectrum of P<sub>2</sub> showed the signals at 2CH<sub>2</sub>-CO (2H) d., δ:2.8 ppm of CH-COOH (1H) and δ:2.4 ppm of CH-COOH (1H) S. polymer, and δ: 1.3 ppm due to CH<sub>3</sub> terminal of (3H) d., of Lactic acid., δ: 4.0 ppm of O-CH (1H) Q., and δ 10.8 ppm of COOH (1H)S., The remained carboxylic acid and Lactic acid.


FTIR spectrum, Fig (3) of 4-aminoantipyrin lactic acryl ester polymer P<sub>3</sub> showed the beak at 3417cm<sup>-1</sup> of remained OH carboxylic and 3277cm<sup>-1</sup> as shoulder beak due to NH amide, 3063cm<sup>-1</sup> of C-H aromatic, 1705cm<sup>-1</sup> is attributed to (carbonyl-ester) and the other absorption appeared at 1722 cm<sup>-1</sup> is for carbonyl acid and the new absorption were appeared at the beak appeared at 1656 cm<sup>-1</sup> is due to carbonyl-amide.

(Drug, 2003; Johnson *et al.*, 2005; Debjit *et al.*, 2012) Fig (4) <sup>1</sup>H-NMR spectrum of polymer P<sub>3</sub> showed the signals 2.7 ppm of 2CH<sub>2</sub>-CO (2H) d., 2.9 ppm of CH-COOH (1H) and 2.8 ppm of CH-COOH (1H) S. polymer, 1.3 ppm of CH<sub>3</sub> terminal (3H)d., δ: 3.6 ppm of CH<sub>3</sub>-N (3H) S., and δ: 2.9 ppm of CH<sub>3</sub>-C (3H) S., δ: 4.8 O-CH-CO (1H) Q., δ: 7.1 ppm (2H)d. of ortho aromatic ring, δ: 7.6 ppm of(3H) T., of meta and para, and δ: 8.1ppm of NH-CO (1H) S. (Ronald Siegel and Michael Rathbone, 2012; Fiyral Mohammad *et al.*, 2015)


The remained carboxylic acid was 40% was tested by titration of polymeric sample with 0.1N of NaOH in the presence of phenolphthalein as an indicator. The concept of polymeric drug has been subjected with medicine chemists as long consideration synthetic polymers.

The polymer which is substituted by drug groups enhanced the using as prodrug polymers. The UV. Spectrum of P<sub>3</sub> gave absorptions at 200 and 400 nm due to. (n-π\*) and (π-π\*) due to electron transition for drug conjugation structures.

Fiyral Mohammad *et al.* (2015) The controlled release rates were studied as drug polymers which could be hydrolyzed in basic and acidic medium due to ester bonds as shown in the following mechanisms Scheme 2 & 3:-



Scheme 2



Scheme 3

## 10. CONCLUSION

It was concluded that the extended side arm of poly acrylic acid with suitable spacer di-functional such as Lactic acid with 4-aminoantipyrine, In basic medium, the rate of hydrolysis is higher than acidic medium this is due to the presence of OH<sup>-</sup> in alkaline, which acts as a stronger nucleophilic attack to carbonyl group with respect to water, and the H<sub>2</sub>O takes place faster hydrolysis than acidic medium, H<sup>+</sup> which is bonded to oxygen atom of ester as shown in Scheme (2). The spacer effect appeared more enhancements in hydrolysis of ester or amide groups.

Fig (5) showed the release profile of drug release (mole fraction) versus time.

A swelling percentage of the prepared polymer was studied which equals to 10%.

The swelling% was calculated according to the following equation.

$$\Delta m = \frac{m_1 - m_0}{m_0} \times 100$$

When:-

m<sub>0</sub> is the weight of dry drug polymer.

m<sub>1</sub> is the swallowed polymer in non-solvent




Fig-1. FTIR spectrum of polymer (P<sub>2</sub>)




Fig-2. <sup>1</sup>H-NMR spectrum of polymer (P<sub>2</sub>)




Figure-3. FTIR spectrum of polymer (P<sub>3</sub>)




Figure-4. <sup>1</sup>H-NMR spectrum of polymer (P<sub>3</sub>)




Figure-5. Drug release of P<sub>3</sub> in PH 1.1 and 7.4 at 37°C at 400nm



## REFERENCES

- Alam, M.S., J.H. Choi and D. Lee, 2012. Synthesis of novel schiff base analogues of 4-amino-1, 5-dimethyl-2-phenylpyrazol-3-one and their evaluation for antioxidant and anti-inflammatory activity. *Bioorg. Med. Chem*, 20(13): 4103-4108.
- Ardeshir, K., S. Davood, S. Minoos and M. Seyed, 2007. Synthesis and characterization of poly (8-Hydroxyquinoline-P-Styrene Sulfonate) and study of its controlled release behavior. *Iranian Polymer Journal*, 16(5): 309-317.
- Avérous, L., 2011. Polylactic acid: synthesis, properties and applications. *Journal of Macromolecular Science, Part C: Polymer Reviews*, 44(3): 77-78.
- Callery, P. and G. Peter, 2002. Cancer and cancer chemotherapy. In: Foye's principles of medical chemistry. David, A.W. and Thomas, L.L. (Eds). 5th Edn., Philadelphia: Lippincott, Williams and Wilkins. pp: 924.
- Debjit, B., G. Harish, K.B. Pragati, S. Duraivel and K.K.P. Sampath, 2012. Controlled release drug delivery systems. *The Pharma Innovation J*, 1(12): 1-16.
- Diab, M.A., 2003. Thermal stability of poly (Acryloyl Chloride) homopolymer and copolymers of acryloyl chloride with methyl acrylate. *Acta Polymerica*, 41(6): 351-354.
- Drug, 2003. Drug delivery technologies—innovations and market challenges. *Scrip Reports* (PJB Publications Ltd).
- Duncan, R., 2006. Polymer conjugates as anticancer nanomedicines. *Nat. Rev Cancer*, 6(9): 688–701.
- Firyal, M.A., 1997. Synthesis, polymerization and isomerization of isoimide. *J. of Polymer Science Part A. Polymer Chemistry*, 35(15): 3125-3130.
- Firyal, M.A., 2005. Modification of acryloylchlorides polymers. *Um-Salama Science Journal*, 2(4): 645-652.
- Fiyral Mohammad, A., H.A.-N. Taghreed and A. Saif Mohsin, 2015. Synthesis and characterization of gelatin-G-poly (AcryloylAmide), proflavine and controlled release study. *Chemical and Process Engineering Research*, 32(1): 53-61.
- Johnson, M., L. Koman and E. Neuse, 2005. Polymeric drug carriers functionalized with pairwise arranged. *J. of Appli. Poly. Sci*, 96(1): 10-19.
- Peter, K. and T. Renata, 2002. Reactive and functional polymers. New York: John Wiley and Sons, 52(1): 11.
- Radi, S., Y. Toubi, I. Hamdani, A. Hakkou, F. Souana, I. Himri and M. Bouakka, 2012. Synthesis, antibacterial and antifungal activities of some new bipyrazolic tripodal derivatives, *res. J. Chem. Sci*, 2(4): 40-44.
- Rautio, J., H. Kumpulainen, T. Heimbach, R. Oliyai, D. Oh, T. Järvinen and J. Savolainen, 2008. Prodrugs, design and clinical applications. *Nat Rev Drug Discov*, 7(1): 255–270.
- Ronald Siegel, A. and J. Michael Rathbone, 2012. Overview of controlled release mechanisms. *Controlled Release Society. Library of Congress Control Number: 2011939206*.
- Soudabeh, D. and A. Ali, 1996. (Synthesis and Hydrolysis of Modified PVA). *Iranian Polymu Journal* 1, 5(3): 96.
- Stella, V., 2010. Prodrugs, some thoughts and current issues. *J Pharm Sci*, 99(12): 4755–4765.
- Testa, B., 2009. Prodrugs, bridging pharmacodynamics/pharm a cokinetic gaps. *Curr Opin Chem Biol*, 13(1): 338–344.

Xinxin, F., 2010. Literature Seminar. Polymeric Conjugates for Anti-Cancer Drug Delivery. September 16.

Yi, L., L. Yuanyuan, W. Haowei, X. Xiaohui, W. Ping and L. Fangshi, 2013. Synthesis, crystal structure, vibration spectral, and DFT studies of 4-aminoantipyrine and its derivatives. *Molecules*, 18(1): 877-893.

*Views and opinions expressed in this article are the views and opinions of the authors, The International Journal of Biotechnology shall not be responsible or answerable for any loss, damage or liability etc. caused in relation to/arising out of the use of the content.*